PDE2A
MOLECULAR TARGETphosphodiesterase 2A
PDE2A (phosphodiesterase 2A) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting PDE2A
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | ly 294002 | 4.84 | 126 |
| 2 | sildenafil | 4.78 | 118 |
| 3 | dipyridamole | 4.03 | 55 |
| 4 | zaprinast | 3.81 | 44 |
| 5 | isobutylmethylxanthine | 3.71 | 40 |
| 6 | vardenafil | 3.18 | 23 |
| 7 | ehna | 2.94 | 18 |
| 8 | pptn | 2.89 | 17 |
| 9 | ehna | 2.71 | 14 |
| 10 | Clofarabine | 0.69 | 1 |
| 11 | Papaverine | 0.69 | 1 |
About PDE2A as a Drug Target
PDE2A (phosphodiesterase 2A) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented PDE2A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
PDE2A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.